Lil­ly backs Or­so­Bio's $60M Se­ries A for PhII tri­als in obe­si­ty and NASH

Or­so­Bio, a biotech fo­cused on obe­si­ty and meta­bol­ic dis­or­ders, is get­ting fi­nan­cial sup­port from one of the lead­ing drug­mak­ers in the field as Eli Lil­ly helps back its $60 mil­lion Se­ries A round.

Or­so­Bio, based in Men­lo Park, CA, is an amal­ga­ma­tion of as­sets from Gilead, Sh­iono­gi, Phenex Phar­ma­ceu­ti­cals and Astel­las, and it al­ready has can­di­dates in hu­man test­ing or clin­i­cal plans for obe­si­ty, type 2 di­a­betes, non­al­co­holic steato­hep­ati­tis, as well as oth­er in­flam­ma­to­ry liv­er and kid­ney dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER